Chinese Ambassador Dong Jinyi Visits IBSA Institut Biochimique SA in Switzerland
(21.04.2009)
On April 21, Chinese Ambassador Dong Jinyi and his wife were invited to Lugano to visit IBSA Institut Biochimique SA, accompanied by Commercial Counselor of the Embassy Wang Heliang, etc. IBSA’s president Dr. Arturo Licenziati, the former Federal President of Switzerland and IBSA’s consultant Mr. Cotti and others accompanied Ambassador Dong and his party to visit the company’s production and operation.
|
| |
Read more
|
|
|
|
|
|
|
 |
Publication of the STudy on Osteoarthritis Progress Prevention (STOPP)
(02.02.2009)
The STOPP publication is the largest available study focused on the structure modifying activity of chondroitin sulfate and it has been recently published in the prestigious journal Arthritis & Rheumatism.
|
| |
Read more
|
|
|
|
|
|
|
|
Flector® Patch and Tirosint® licensed for the US market
(24.08.2007)
IBSA announces the signature of the licensing agreement with Alpharma Inc. for the marketing of Flector® Patch and Tirosint® in the US market.
|
| |
Read more
|
|
|
|
|
|
|
|
Flector Tissugel ® approved by the FDA
(31.01.2007)
Flector Tissuegel®, IBSA's patch containing 1.3% epolamine salt of diclofenac, has been approved by the FDA for the treatment of acute pain due to minor strains, sprains and contusion. The USA marketing authorisation enlightens another major achievement and a further confirmation of the expansion trend of the company.
|
| |
Read more
|
|
|
|
|
|
|
|
Tirosint® ready to enter the USA market
(13.10.2006)
Tirosint®, IBSA's L-thyroxin in soft gel capsules, has been approved by the FDA for the introduction in the USA market. Effective immediately, the US Marketing Authorisation represents a milestone achievement in IBSA's international expansion as well as a further outcome of the technological development of the company.
|
| |
Read more
|
|
|
|
|
|
|
|
